a Oakland University William Beaumont School of Medicine.
Am J Bioeth. 2017 Jun;17(6):36-42. doi: 10.1080/15265161.2017.1314042.
Nocebo effects occur when an adverse effect on the patient arises from the patient's own negative expectations. In accordance with informed consent, providers often disclose information that results in unintended adverse outcomes for the patient. While this may adhere to the principle of autonomy, it violates the doctrine of "primum non nocere," given that side-effect disclosure may cause those side effects. In this article we build off previous work, particularly by Wells and Kaptchuk ( 2012 ) and by Cohen ( 2013 ), to suggest ethical guidelines that permit nondisclosure in the case when a nocebo effect is likely to occur on of the basis of nonmaleficence. We accept that that autonomy vis-à-vis informed consent must be forestalled, but salvage much of its role by elaborating a practical clinical approach to postencounter follow-up. In doing so, we reconcile a clinically practicable process of determining conditions of disclosure with long-standing ethical commitments to patients.
当患者自身的负面预期对患者产生不良反应时,就会产生反安慰剂效应。根据知情同意,提供者通常会披露信息,从而导致患者出现意外的不良后果。虽然这可能符合自主原则,但它违反了“首要原则”,因为副作用披露可能会导致这些副作用。在本文中,我们在前人的工作基础上进行了扩展,特别是 Wells 和 Kaptchuk(2012)和 Cohen(2013)的工作,提出了在可能出现反安慰剂效应的情况下允许不披露的道德准则,这是基于不伤害原则。我们承认,在知情同意的情况下,自主权必须被阻止,但通过详细阐述事后随访的实际临床方法,挽救了其大部分作用。这样,我们就将确定披露条件的临床可行过程与对患者的长期道德承诺协调起来。